Key Points
- Director Kathy Hibbs sold 6,250 SOPHiA GENETICS shares at an average price of $8.13, totaling $50,812.50. The sale, made under a pre-arranged Rule 10b5-1 plan, reduced her holdings by 6.05% to 96,992 shares.
- SOPH shares opened at $7.61, near the upper end of their $3.10–$8.98 one-year range. The company reported a quarterly revenue beat but missed earnings estimates, posting a loss of $0.26 per share versus the expected $0.21 loss.
- Analyst sentiment is mixed, with three Buy ratings, one Hold and one Sell; the consensus rating is Hold with a $10.00 price target. Institutional investors own 31.59% of the company.
SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) Director Kathy Hibbs sold 6,250 shares of SOPHiA GENETICS stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $8.13, for a total transaction of $50,812.50. Following the sale, the director directly owned 96,992 shares in the company, valued at $788,544.96. The trade was a 6.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
SOPHiA GENETICS Stock Performance
Shares of SOPH opened at $7.61 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The firm has a market capitalization of $638.40 million, a PE ratio of -6.62 and a beta of 0.98. The company has a 50-day simple moving average of $6.98 and a two-hundred day simple moving average of $5.67. SOPHiA GENETICS SA has a one year low of $3.10 and a one year high of $8.98.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The business had revenue of $23.31 million for the quarter, compared to analysts' expectations of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. On average, analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.
Institutional Trading of SOPHiA GENETICS
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AWM Investment Company Inc. bought a new stake in shares of SOPHiA GENETICS during the 2nd quarter worth approximately $9,809,000. Sei Investments Co. bought a new position in SOPHiA GENETICS in the 1st quarter valued at $1,772,000. Maven Securities LTD purchased a new stake in SOPHiA GENETICS in the second quarter worth $866,000. 1492 Capital Management LLC purchased a new stake in SOPHiA GENETICS in the fourth quarter worth $973,000. Finally, Royce & Associates LP bought a new stake in shares of SOPHiA GENETICS during the fourth quarter worth $2,009,000. 31.59% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
SOPH has been the topic of several research reports. Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. HC Wainwright lifted their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, BTIG Research upped their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $10.00.
Check Out Our Latest Stock Analysis on SOPHiA GENETICS
SOPHiA GENETICS Company Profile
(
Get Free Report)
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
